Abstracts

Rationale: We have set up a epilepsy registry for identifying the epilepsy diagnostic patterns, trial of various AEDs medication, the treatment efficacy, and adverse events of AEDs by using an our hospital-based, prospective registry with a computerized database, named by The Seoul National University Hospital Epilepsy Registry (SNUHER). Methods: SNUHER study has registered patients (18-80 years of age) with epilepsy, which was confirmed by clinical symptoms, electroencephalography, and brain imaging studies. The patient record consists of demographic factors, clinical features, diagnosis, treatment, and clinical outcome. We have measured the serum concentrations of current AEDs and obtained the samples for analysis of variable pharmacogenetic factors, including variation in genes encoding drug target, drug transport, drug metabolizing, and human leucocyte antigen proteins. Results: The database collection was started in February 2011, 1492 patients were eligible for this study. 50.7% were males and median age was 38.56 years old. Diagnostic epilepsy classification included generalized epilepsy 14.9%, localization-related epilepsy 82.9%, and unknown cause 2.2%. In generalized epilepsy, 50.5% were maintained on monotherapy. The most commonly used drugs were lamotrigine(40.3%) and levetiracetam(37.5%). In localization-related epilepsy, 28.9% were maintained on monotherapy and most commonly used drugs were oxcarbazepine(45.7%). Seizure free rate were 77.9% in generalized epilepsy and 61.7% in localization-related epilepsy. Conclusions: We have successfully established the web-based clinical database, named SNUHER. This prospective hospital-based registry allows us to identify and quantify the various clinical outcomes. At the same time, we obtained the current AEDs serum concentration and the samples for analysis of variable pharmacogenetic factors. Through this, we are presented the basis of individualized therapeutic strategies.